Pensare (WRLS) Announces Intent to Adjourn Vote to July 31st
by Kristi Marvin on 2019-07-30 at 8:59am

Pensare Aquisition Corp. (WRLS) announced this morning that they intend to adjourn today’s extension vote.  Instead, the vote will be held tomorrow, July 31st, at which, shareholders will be asked to approve a four-month extension of their deadline to December 1, 2019.

As a reminder, Pensare does not intend to make any additional contributions to trust after August 1st.  However, we do know that Pensare, which currently has an estimated $63 million in trust, intends to acquire Computex for an aggregate of approximately $65 million in cash, stock, and assumed debt. So by not offering a contribution, it would appear Pensare is trying to reduce the trust amount via redemptions and possibly replace some of that loss (if it is significant) with a new PIPE.

If you recall, in Pensare’s previous proxy filing regarding the extension vote, they stated:

“The withdrawal of funds from the trust account in connection with the Election will reduce the amount held in the trust account following the redemption, and the amount remaining in the trust account may be significantly reduced from the approximately $63 million that was in the trust account as of June 19, 2019. In such event, Pensare may need to obtain additional funds to complete a business combination and there can be no assurance that such funds will be available on terms acceptable to the parties or at all.”

However, why is Pensare delaying the vote just one day?  Seems to be cutting it pretty close to their deadline of August 1, 2019. Maybe there is some administrative issue or maybe they just want to delay having to release the results of that vote to next week (per the rules, vote results aren’t due for 4 business days, although most companies release their results much earlier than that).

Regardless, per Pensare’s statement above, there is the added risk of a new PIPE (post-vote) done a price below $10.00.  Layer in a four-month extension without any contribution to trust for remaining shareholders and that means redemptions are going to be HEAVY.

Stay tuned for any further updates.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved